Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2013

01-10-2013 | Letter

Misuse of blood serum to assess exposure to bisphenol A and phthalates

Authors: Antonia M Calafat, Holger M Koch, Shanna H Swan, Russ Hauser, Lynn R Goldman, Bruce P Lanphear, Matthew P Longnecker, Ruthann A Rudel, Susan L Teitelbaum, Robin M Whyatt, Mary S Wolff

Published in: Breast Cancer Research | Issue 5/2013

Login to get access

Excerpt

We noted serious methodologic issues in the measurement of bisphenol A (BPA), phthalate diesters, and their metabolites in blood serum and other tissues, as reported in the recent Breast Cancer Research article by Sprague and colleagues [1]. Such measurements are analytically possible. However, for the reasons that follow, it is seldom possible to verify that serum concentrations of these compounds are valid measures of exposure. …
Literature
1.
Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JD, Hampton JM, Buist DS, Bowles EJ, Sisney GS, Burnside ES: Circulating serum xenoestrogens and mammographic breast density. Breast Cancer Res. 2013, 15: R45-10.1186/bcr3432.CrossRefPubMedPubMedCentral
2.
Calafat AM, Needham LL: What additional factors beyond state-of-the-art analytical methods are needed for optimal generation and interpretation of biomonitoring data?. Environ Health Perspect. 2009, 117: 1481-1485.CrossRefPubMedPubMedCentral
3.
Koch HM, Kolossa-Gehring M, Schröter-Kermani C, Angerer J, Brüning T: Bisphenol A in 24 h urine and plasma samples of the German Environmental Specimen Bank from 1995 to 2009: a retrospective exposure evaluation. J Expo Sci Environ Epidemiol. 2012, 22: 610-616. 10.1038/jes.2012.39.CrossRefPubMed
4.
5.
Longnecker MP, Harbak K, Kissling GE, Hoppin JA, Eggesbo M, Jusko TA, Eide J, Koch HM: The concentration of bisphenol A in urine is affected by specimen collection, a preservative, and handling. Environ Res. in press
6.
Ye X, Zhou X, Hennings R, Kramer J, Calafat AM: Potential external contamination with bisphenol A and other ubiquitous organic environmental chemicals during biomonitoring analysis: an elusive laboratory challenge. Environ Health Perspect. 2013, 121: 283-286. 10.1289/ehp.1206093.CrossRefPubMedPubMedCentral
Metadata
Title
Misuse of blood serum to assess exposure to bisphenol A and phthalates
Authors
Antonia M Calafat
Holger M Koch
Shanna H Swan
Russ Hauser
Lynn R Goldman
Bruce P Lanphear
Matthew P Longnecker
Ruthann A Rudel
Susan L Teitelbaum
Robin M Whyatt
Mary S Wolff
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3494

Other articles of this Issue 5/2013

Breast Cancer Research 5/2013 Go to the issue

Research article

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Research article

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

Research article

A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients

Research article

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Viewpoint

AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?

Research article

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits